



We, LTT Bio-Pharma, have been applying cutting-edge science and technology to medicine for more than 30 years, have been conducting research and development to protect the health and lives of people all over the world.
Research and Development
We will introduce our original drug discovery technologies, pipeline under development, and launched drugs.
DR
Drug Repositioning
We were the first in Japan to point out the importance of DR and have been promoting drug discovery as a leading
DR company. We are also engaged in collaborative research using our own original library of approved drugs.


DDS
Drug Delivery System
Like DR, DDS contributes to early commercialization and reduced development risk. We have launched DDS new drug and are still developing new drugs using the world’s first DDS technology.
Collaborative R&D
and Consultation
Through joint development, we connect academia and pharmaceutical companies to efficiently develop pharmaceuticals.

Founding Family
創業者と創業家 / 水島徹 & 水島広子

Corporate Information
Careers
IR Information
- All
- Business Development
- Drug Discovery
- General Meeting of Shareholders
- Financial Information
- Other
-
2025.06.05
Partial correction of the contents of the” Announcement of the 23rd Ordinary General Meeting of Shareholders”
-
2025.06.05
Announcement of the 23rd Ordinary General Meeting of Shareholders
-
2025.05.29
Announcement of our CEO’s appointment as a director of the SAMURAI Biotech Association
-
2025.05.28
Report on the International Seminar Held at the 78th Annual Meeting of the Japanese Society for Oxidative Stress Research
-
2025.05.28
Report on the International Seminar Held at the 78th Annual Meeting of the Japanese Society for Oxidative Stress Research
-
2025.05.15
Notice Regarding Conclusion of Joint Development Agreement
-
2025.05.13
Announcement of publication of paper on joint research with the National Institute for Quantum and Radiological Science and Technology
-
2025.03.18
Announcement of a presentation at the 22nd Annual Meeting of the Japanese Society of Medical Oncology (JSMO2025)
-
2025.06.05
Partial correction of the contents of the” Announcement of the 23rd Ordinary General Meeting of Shareholders”
-
2025.06.05
Announcement of the 23rd Ordinary General Meeting of Shareholders
-
2025.03.18
Notice of Resolutions of the 22nd Ordinary General Meeting of Shareholders
-
2025.03.18
Announcement of the 22nd Ordinary General Meeting of Shareholders
-
2025.05.29
Announcement of our CEO’s appointment as a director of the SAMURAI Biotech Association
-
2025.05.21
Meeting with Mr. Tse Ping, founder of Sino Biopharmaceutical Limited and Vice Chairman of our Board of Directors, and our CEO
-
2025.05.13
Request for notification of changes to shareholder register entries, such as address changes
-
2025.03.26
Announcement of the renewal of the business partnership agreement with Sino Biopharmaceutical Limited
